Abstract
Background
Human epididymis protein 4 (HE4), also known as WFDC2, was discovered in 1991 and named because of its specific expression in epithelial cells of the epididymis [1] . In 1999, Schummer et al. [2] compared genomic hybridizations and found that HE4 was also highly expressed in ovarian cancer, which raised expectations of an early diagnostic test for this insidious cancer.
Subsequently, Hough et al. [3] completed a large-scale analysis of the gene expression profiles of ovarian cell lines and tissues using serial analysis of gene expression (SAGE) technologies, and also found high expression of HE4 in ovarian cancer. Compared with cancer antigen 125 (CA125), the positive rate of HE4 is lower in benign disease, which increase the sensitivity of HE4 to the diagnosis of ovarian cancer. In 2003, HE4 was recognized as a serum marker of ovarian cancer [4] , leading to increased studies of HE4 in other cancers. However, althought many studies showed that HE4 was highly expressed in ovarian cancer, its expression in other malignant tumors and normal tissues was also high, albeit to different extents. In 2006, Galgano et al. [5] measured the expression of HE4 in normal and malignant tissues by using oligonucleotide and tissue chips. They found that HE4 was highly expressed in normal trachea, the salivary glands and female reproductive tract. Among tumors, HE4 expression was highest in ovarian cancer. High expression level of HE4 was also observed in pulmonary adenocarcinoma, transitional cell carcinoma, and breast and pancreatic cancer. Our preliminary studies have demonstrated that in addition to ovarian cancer [6] , HE4 was also highly expressed in endometrial cancer [7] , emphasis that how the specificity of HE4 as a serum marker of ovarian cancer needs to be reassessed.
In protein mass spectrometry, we found a HE4 interacting protein, annexin A2 (ANXA2). HE4/ANXA2 interaction was confirmed by GST pull-down and co immunoprecipitation. HE4/ANXA2 promoted the invasion and migration of ovarian cancer cells. In the past 24 years since the discovery of HE4, There's been amount of research into the HE4 clinical application, but little is known about its biological functions and mechanisms. Our preliminary studies have shown that the proliferation, invasion, migration, drug resistance and other functions of ovarian cancer cells increased after upregulate of HE4 expression, or after treated with HE4 active protein [8] [9] [10] . ANXA2, a member of the annexin family, is a calcium-dependent, membrane phospholipid-binding protein [11] present in several cell types that can regulate membrane transport, signal transduction, differentiation, apoptosis and other biological functions of cells [12] . The expression of ANXA2 has been found in various malignant tumors [13] . ANXA2 is closely related to the occurrence and development of several malignant tumors and plays an important role in angiogenesis, proliferation, apoptosis, adhesion, invasion and migration of tumor cells [14] .
According to our preliminary studies, ANXA2 is highly expressed in ovarian [15] and endometrial cancers [16] , and HE4 and ANXA2 also show co-localization in endometrial carcinoma. However, so far, there is no research reporting whether this interaction exsists in other malignant tumors. This study examined the expression of HE4 and ANXA2 in malignant tumor cells originated from different tissues. We also determined whether the HE4/ ANXA2 interaction was ubiquitous in these cells and whether changes of their expression affected biological behaviors such as proliferation, adhesion, invasion, and migration. Overall, we aime to provide a comprehensive evidence for the expression and biological functions of HE4 and ANXA2 in malignant tumors.
Methods

Cell culture and transfection
An ovarian cancer cell line (CaoV-3、ES-2、OVCAR3), endometrial carcinoma cell lines (Ishikawa), lung cancer cell line (A549), cervical cancer cell line (Hela), hepatic carcinoma cell line (HepG2), gastric cancer cell line (HGC-27), colon carcinoma cell lines (SW480, HT29) and human embryo kidney cell line (HEK293) were cultured according to the manufacturer's protocol. All of the cell lines used in the experiment were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. ES-2 was propagated in McCoy's 5A modified medium with 10% fetal bovine serum; HepG2, HEK293 were propagated in DMEM high glucose medium with 10% fetal bovine serum; other cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum. All the cell lines were grown at 37 °C in a 5% CO 2 /95% air atmosphere and were revived every 3 to 4 months.
Transfection reagent kits are purchased from invitrogen reagent company. pEGFP-N1-ANXA2 plasmids are purchased from Shanghai GenecChem, and according to the plasmid transfection specifications, this plasmid is transfected into HEK293 cells and stably construct cell line 293-A2. The lentivirus-mediated HE4 shRNA sequence is: 5′-GTC CTG TGT CAC TCC CAA T-3′, and the control sequence 5′-TTC TCC GAA CGT GTC ACG T -3′. The targeting sequences were cloned into GV248 vector (Shanghai GeneChem). The depletion efficiency was evaluated by western blot analysis.
Real-time PCR
Cells were added with Trizol reagent (1 mL per 10 7 cells) to extract total RNA. cDNA was synthesized according to the RNA reverse transcription kit instructions (TAKARA, DRR037A). The sequences of HE4 gene primer were 5′-TGC CCC CAG GTG AAC ATT AAC-3′ for forward primer and 5′-CCA TTG CGG CAG CAT TTC AT-3′ for reverse primer. The sequences of ANXA2 gene primers were 5′-CTG CTC CAG AAC CAA CCA G-3′ for forward primer and 5′-TGC GGA AGT CAC CAG ATG T-3′ for reverse primer. The sequences of GAPDH primers were 5′-ATG GAA ATC CCA TCA CCA TCTT-3′ for forward primer and 5′-CGC CCC ACT TGA TTT TGG -3′ for reverse primer. The Light Cycler PCR system (Roche Diagnostics, Mannheim, Germany) was used for real-time PCR amplification and Ct value detection. The melting curves were analyzed after amplification. PCR reactions of each sample were done in triplicate. Data were analyzed through the comparative threshold cycle (CT) method.
Immnocytochemistry staining
Cells at exponential phase of growth were digested by 0.25% trypsin and cultured in medium containing 10% FBS to prepare single-cell suspension. Cells were washed twice with cold PBS when growing in a single layer, and fixed with 4% para-formaldehyde for 30 min. The expression of ANXA2 and HE4 on cells were detected according to the SABC kit instructions. The working concentrations of primary antibodies against HE4 and ANXA2 used were 1:50 (Abcam, America, Cat. No. ab200828) and 1:300 (Proteintech, America, Cat. No. 66035-1-Ig), respectively. The primary antibody was replaced by rabbit IgG for negative control.
Co-immunoprecipitation and western blot
Ice-cold RIPA buffer (1 ml) was added to cells, followed by incubation for 30 min at 4 °C. After centrifugation at 15,000×g for 30 min at 4 °C, the supernatant was collected and treated with 10 μl of mouse anti-ANXA2 monoclonal (Proteintech, America, Cat. No. 66035-1-Ig) or goat anti-HE4 polyclonal antibody (Santa Cruz Biotechnology, Inc, America, Cat. No. sc-27570) for 3 h at 4 °C. Then, 20 μl of protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Inc) was added, followed by incubation on a rocker platform overnight at 4 °C. The primary antibody was replaced by mouse or goat IgG (Bioss, China) as negative control. Immunoprecipitates were subsequently subjected to 12% SDS gel electrophoresis and analyzed via western blot using rabbit polyclonal HE4 (Abcam, America, Cat. No. ab109298) and mouse monoclonal ANXA2 antibodies (Proteintech, America, Cat. No. 66035-1-Ig). Proteins were visualized using ECL reagent (Thermo scientific ECL). The experiments were repeated three times.
Double-labeling immunofluorescence method
Cells in the exponential phase of growth were digested with 0.25% trypsin and cultured in medium containing 10% FBS to prepare single-cell suspension. Cells were washed twice with cold PBS when growing in a single layer, and fixed with 4% para-formaldehyde for 30 min. The cells were simultaneously incubated with primary antibodies against HE4 (Abcam, America, Cat. No. ab200828) and ANXA2 (Proteintech, America, Cat. No. 66035-1-Ig). The primary antibody was replaced by rabbit or mouse IgG for negative controls. The working concentrations of fluorescein isothiocyanate (FITC) and tetraethyl rhodamine isothiocyanate (TRITC) were 1:50. Nuclei were counterstained with DAPI. The empirical procedure was performed according to the manufacturer's instructions.
Wound healing
Cells during the log phase were selected and seeded into 6-well plates. When cell confluence was 90%, the cells were starved with serum-free medium overnight. Then scrathed the plate straightly with 10 µl pipette. Cells were cultured in medium without serum. After 24 h, the width of the scarification were observed via inverted microscope (DMI3000B, Leica, Germany) with 100× magnification. Wound-healing percentage of the cells was determined by the ratio of healing width at each time point to the wound width at 0 h.
Invasion assays
Cell invasion assay were performed using transwell chamber with pore size of 8 μm. For the invasion assay, 2 × 10 5 cells were seeded in 200 μl serum-free medium in the upper chamber coated with matrigel (BD Biosciences, NJ, USA). The pipette tip was pre-cooled, and the ECM gel was melted at 4 °C overnight, diluted by 1:8 with serum free medium. Complete medium was added to the lower chamber. After 24 h or 48 h incubation at 37 °C, cells in the upper chamber were carefully removed with a cotton swab and the cells traversed to the back membrane of the chamber were fixed in 4% para-formaldehyde and stained with 0.1% crystal violet. For quantification, five fields (upper, lower, left, right, middle × 400) per filter were counted under a microscope (DMI3000B, Leica, Germany).
Cell proliferation test
Cellular proliferation was analyzed by CellTiter 96 R AQ ueous One Solution Cell Proliferation Assay (Promega, USA). Cells were seeded at a density of 10 3 per well in 96-well culture plate. Cell proliferation was detected at 24, 48, 72 h, respectively. 100 μl medium were added with 20 μl MTS, followed by incubation for 2 h. The optical density at 490 nm was measured on an ELX-800 spectrometer reader (Bio-Tek Instruments, Winooski, USA).
Cell-cycle analysis
Cells were harvested and washed with PBS for three times. Then, they were fixed with 70% cold ethanol at 4 °C overnight. Cells were resuspended and washed with PBS, then resuspended in 100 μl RNase, 37 °C for 30 min. Then added 400 μl propidium iodide (PI), 4 °C in dark for 30 min, and quantified by FACSCalibur (BD Biosciences, San Jose, CA, USA). The empirical procedure was performed according to the manufacturer's instructions and repeated for three times.
Adhesion test
Cells were seeded in 96-well plates at a density of 2 × 10 3 per well and incubated at 37 °C for 10, 30, 60 min, then washed with PBS to remove non-adherent cells. Adherent cells were fixed with 4% para-formaldehyde, after washed by PBS, cells were stained with crystal violet. Washed with PBS and added 2% SDS to terminate the reaction. The optical density at 570 nm was measured on an ELX-800 spectrometer reader (Bio-Tek Instruments, Winooski, USA).
Statistical analysis
SPSS version 17.0 (SPSS Inc, Chicago, IL) software was used for statistical analysis. χ 2 analysis, variance analysis, and t test were employed. p < 0.05 was considered statistically significant.
Results
HE4 and ANXA2 were highly expressed in various malignant cells
We detected protein and mRNA expression levels of HE4 and ANXA2 in nine types of malignant cells lines (ES-2, CaoV3, A549, HeLa, HepG2, Ishikawa, HGC-27, SW480 and HT29) and Human Embryonic Kidney 293 cell line by western blot (Fig. 1a), immunocytochemistry (Fig. 1b) and real-time PCR (Fig. 1c) . The results show that HE4 
Interaction and co-localization of HE4 and ANXA2 are common in various malignant cells
We further studied the HE4-ANXA2 interaction in different cell lines by co-immunoprecipitation and double-label immunofluorescence assays. Co-immunoprecipitation (Fig. 2a, b) revealed that the interaction between HE4 and ANXA2 was in various malignant cell lines including CaoV3, ES-2, OVCAR-3, Ishikawa, A549, HGC-27, SW480, HepG2, Hela, HT29 and HEK293 cell line. The results of the double-label immunofluorescence assay (Fig. 2c) showed that the co-localization of HE4/ANXA2 was on the cytoplasm and membrane of HEK293 and various malignant tumor cells including SW480, ES-2, A549, HT29 and HGC-27.
Cells expressing higher level of HE4 and ANXA2 show stronger ability of proliferation, adhesion, invasion and metastasis
We found several cell lines with distinct expressions of HE4 and ANXA2 gene and protein through western blot (Fig. 3a) and real-time PCR (Fig. 3b) : ES-2 has high expression of both HE4 and ANXA2; HEK293 has high expression of HE4 but relatively low expression of ANXA2; HT29 has high expression of ANXA2 but relatively low expression of HE4; HGC-27, with relatively low expressed of both HE4 and ANXA2.
The cell cycle of above four types of cell lines was detected by flow cytometry. The results showed that the G1 phase of both ES-2 and HT29 cells was lower than that of HEK293 and HGC-27, And the difference was statistically significant (p < 0.05) (Fig. 4a) . The proliferative capacity of ES-2 and HT29 was significantly higher than that of HGC-27 and HEK293 cell lines by MTS assay (all p < 0.05). Both ES-2 and HT29 cell lines are highly expressed of ANXA2, which indicated that ANXA2 may play an important role in the proliferation of malignant cells (Fig. 4b) .
Cell adhesion plays an important role in drug resistance, invasion and metastasis of malignant tumors. We compared the adhesion capacity of above four types of cells by adhesion experiments. The results showed that the number of ES-2 cells adhering to the culture plate at 10 min, 30 min, and 60 min was significantly higher than that of the other three type of cell lines (p < 0.05). ES-2 has high expression of both HE4 and ANXA2, which indicated that a concomitant high expression of HE4 and ANXA2 might promote the adhesion behavior of tumor cells (Fig. 4c) .
The migration ability and invasive ability of the cells were detected by scratch test, matrigel-transwell chamber assay. The results showed that migration and invasion ability of ES-2 was significantly stronger than those of HGC-27 and HT29 (p < 0.05). HE4 expression level of ES-2 was higher than that of HGC-27 and HT29, which both cell lines had relatively low expressing of HE4. The above results suggested that HE4 might play an important role in invasion and metastasis of tumor cells (Fig. 4d, e) .
HE4-ANXA2-MMP2 form a protein complex which works together to promote cell migration
Co-immunoprecipitation was used to detecte the interaction between HE4/ANXA2 and MMP2. The results showed interaction between HE4/ANXA2 and MMP2 was common in various malignant tumor cells including CaoV3, ES-2, OVCAR-3, Ishikawa, A549, HGC-27, SW480, HepG2, Hela, HT29 and HEK293 cell lines (Fig. 5a ). Immunofluorescence assay revealed co-localization of ANXA2 and MMP2 in HEK293 cells and they were co-expressed in cell membranes and cytoplasm (Fig. 5b) .
The result of western blot and transwell migration experiments demonstrated the expression of ANXA2, MMP2 and ability of cell migration decreased when HE4 gene was silenced in HEK293 and CaoV3 cell lines, and recovered after adding human recombinant ANXA2 active protein (Fig. 5c-e, g ). At the same time, ANXA2 over or down-expression caused the same changes in MMP2 expression (Fig. 5f ) . The above results suggested that HE4 might regulate MMP2 expression via ANXA2 to affect cell invasion and migration.
Discussion
HE4 protein is encoded by the WFDC2 gene and contains two WAP domains; it is considered to be homologous to the extracellular proteinase inhibitor, SLPI protein because of its structural specificity. HE4 has been found in the epithelial cells of the distal spermatic duct and may be involved in sperm maturation [1] . Subsequent studies [2] showed that HE4 was very highly expressed in ovarian cancer but barely expressed in normal ovarian epithelium, which made it an ideal candidate marker for ovarian cancer with approval for its use in a clinical application [4] . However, additional studies demonstrated that, in addition to ovarian cancer, HE4 expression was not only in normal tissues but also in both benign and Fig. 2 Co-localization of HE4 and ANXA2 in different kinds of cells. a Immunoprecipitation of ANXA2-HE4 complex by anti-HE4 antibody and western blot analysis with anti-ANXA2 antibody; "input" is total cell lysates, "NTC" is negative control without protein; b immunoprecipitation of ANXA2-HE4 complex by anti-ANXA2 antibody and western blot analysis with anti-HE4 antibody; c double-labeling immunofluoscence showed the co-localization of HE4 and ANXA2 in different cells, "blue" represents nucleus; "orange" represents the co-localization of ANXA2 and HE4. The scale ruler represents 50.0 μm malignant diseases to varying degrees [17] , which has serious doubts about the specificity of HE4 and its use as a biomarker for this cancer [18] . The biological function of HE4 in malignant tumors is also controversial. Some investigators suggested HE4 played an inhibitory role in the proliferation and migration of malignant tumors or certain benign lesions. A study completed by Gao et al. [19] showed that HE4 facilitated the apoptosis and adhesion of ovarian cancer cells, while inhibiting the proliferation, migration, and invasion of these cells. In 2013, Kong et al. [20] found, using in vitro stable transfection techniques, HE4 could suppress the proliferation of ovarian cancer cells. These authors showed that HE4 inhibited the proliferation of ovarian cancer cells via MAPK and PI3K/ AKT signaling pathways in vitro, but did not affect EGFR phosphorylation. Other investigators proposed that HE4 promoted the proliferation, drug resistance, invasion, and migration of ovarian or endometrial cancers. In 2012, Lu et al. [21] found, in in vivo and in vitro studies, that HE4 regulated EGFR and Erk1/2 phosphorylation to promote the proliferation of ovarian cancer. In 2013, Moore et al. [22] further found that a high HE4 serum level was related to drug resistance and a shortened survival time for patients with epithelial ovarian cancer. This group also demonstrated that a increased HE4 expression facilitated the growth of tumor and chemotherapy resistance to cisplatin, leading to decreased survival rate in nude mice. However, a decreased HE4 expression inhibited tumor formation in nude mice and HE4 could respond to tumor microenvironment components. EGFR, IGF1R and HIF1α interacted with HE4, the expression of which increased and nuclear translocation occurred after EGF, VEGF and insulin treatment. These results suggested that HE4 probably played an important role in the formation of ovarian cancer tumors. In 2011, Moore et al. [23] found, that serum HE4 expression was associated with muscular invasion of endometrial cancer. Furthermore, a study in 2013 by Li et al. [24] demonstrated that HE4 promoted proliferation and invasion of an endometrial cancer cell line. A study completed by Lu et al. in 2015 [25] showed that treatment with human HE4 recombinant active protein increased the viability and proliferation of pancreatic and endometrial cancer cells, and that cell lines with highly expressed levels of HE4 caused subcutaneous tumor formation in nude mice. In response to the controversies surrounding the biological functions of HE4 in ovarian cancer cells, our research group previously examined these biological functions in in vivo and in vitro models by transfection and silencing of HE4, and by adding HE4 active protein to cultured cells [8, 9, 26, 27] . We found that HE4 promoted not only proliferation, but also the invasion and migration of ovarian cancer cells. Additionally, HE4 expression in ovarian cancer tissues positively correlated with the adhesion molecules CD44, integrin β1, and integrin α5.
ANXA2 is a HE4-interacting protein in ovarian cancer which was discovered by our research group through mass spectrum analysis in the preliminary phase [9] . ANXA2, a member of the annexin family, is a calciumdependent membrane phospholipid-binding protein that plays an important role in several physiological and pathological processes, particularly in tumorigenesis [15] . ANXA2 is usually present in a monomer or heterotetramer form. The ANXA2 monomer exists in the cytoplasm, while the ANXA2 heterotetramer is located in the membrane and is composed of two ANXA2 monomers and two p11 (S100A10) protein monomers [28] . The ANXA2 monomer translocates to the cell membrane due to heat stress, tyrosine phosphorylation, and by interaction with heat shock protein 90α [29] [30] [31] [32] . Intracellular ANXA2 is involved in such physiological processes as exocytosis, endocytosis and membrane transport [33] [34] [35] [36] ; its interaction with CD44 plays an important role in lipid raft formation and signal transduction [37] . ANXA2, as a radioreactive protein, can hinder radiationinduced apoptosis by regulating NF-κB nuclear translocation [38] .
In order to further substantiate whether HE4 and ANXA2 interaction is ubiquitous in malignant tumor cells, we detected the expression and interaction of HE4 and ANXA2 in different malignant tumor cell lines, and then compared the differences between the proliferation, invasion, migration and adhesion of cell lines with different expressions level of HE4 and ANXA2. The results showed that HE4 and ANXA2, both located in the membrane and cytoplasm, were highly expressed and widely interacted in various malignant tumor cells. Cell lines that expressed high levels of HE4 and ANXA2 showed the greatest ability in invasion, migration, proliferation, and adhesion. Cell lines with high level of ANXA2 showed higher proliferation ability.
MMP2, is a matrix hydrolase that specifically dissolves IV collagen in matrix metalloproteinase family; Its expression is positively correlated with tumor progression, metastasis, and poor prognosis [39, 40] . A study by LeBleu et al. [41] showed that HE4 expression in fibrotic renal tissues was high, and the activities of MMP2 and MMP9 were suppressed. What is the mechanism by which HE4 promotes invasion and metastasis in malignant tumor cells? Studies have shown that extracellular ANXA2 acted as a co-receptor for tissue plasminogen activator and plasminogen to promote fibrinolytic protein formation, activate MMPs and promote degradation of extracellular matrix which provided favorable conditions for cell to perform invasion and metastasis [42] . In pulmonary adenocarcinoma and liver cancers, decreased expression of ANXA2 after ANXA2 knockdown was followed by decreased expression of MMP2, as well as decreased proliferation, migration and invasion ability [43, 44] . We examined the interaction among HE4, ANXA2 and MMP2 in various malignant tumor cell lines and the tool cell line HEK293, according the results, it was inferred that HE4, ANXA2, and MMP2 might form a protein complex. We constructed HE4 -silenced HEK293 cell line and HE4 or ANXA2 over-or down-expression CaoV3 cell line model, found that the expression of ANXA2, MMP2 and ability of cell migration decreased when HE4 gene was silenced, and recovered after adding human recombinant ANXA2 active protein. At the same time, ANXA2 over or downexpression caused the same changes in MMP2 expression. Therefore, we speculated that HE4 might affect the expression and function of MMP2 via ANXA2, thereby promoting cell metastasis.
In conclusion, this study has revealed that HE4 is expressed in several malignant tumor types where it interacts with ANXA2 to facilitate invasion, migration, adhesion, and proliferation. HE4, ANXA2 and MMP2 can form a protein complex. HE4 also promotes cellular invasion and migration through influencing MMP2 expression via ANXA2. These findings provides an important experimental basis for the biological function of HE4 and ANXA2 in the progression of malignant tumors.
